On May 23, 2018, we published revised versions of our Privacy Policy and User Agreements. Please read these updated terms and take some time to understand them. Your use of our services is subject to these revised terms.
Yes, I Agree.
Stocks To Buy Now

Blog


Kaival Brands Innovations Group Inc. (KAVL) Seeks to Bring Innovative New Offering to Vape Scene

  • KAVL recently announced the Bidi(TM) Vapor Premarket Tobacco Product Application submission to FDA, a premium recyclable vape pen
  • Application includes 285,000 pages with science-backed evidence that Bidi(TM) Sticks are Appropriate for Protection of Public Health (“APPH”)
  • KAVL and Bidi(TM) Vapor fully support proper regulation of safety manufacturing and marketing of vape products
  • Bidi(TM) Sticks are produced in 11 flavors with 6% nicotine concentration

With a focus on growing and incubating innovative products into mature dominant brands, Kaival Brands Innovations Group (OTCQB: KAVL) recently entered into a partnership with Bidi (TM) Vapor, LLC for exclusive global distribution rights for the Bidi(TM) Stick – a new game-changing recyclable vape pen that offers users a premium multi-flavored vaping experience. Bidi(TM) Vapor recently announced that it has submitted its Premarket Tobacco Product Application (“PMTA”) to the U.S. Food and Drug Administration (“FDA”) for approval to continue its marketing efforts in the United States.

Vape pens, also known as electronic cigarettes, are devices used to supplement nicotine with vapor instead of smoke from combustible cigarettes. Accordingly, Bidi(TM) Vapor’s application provides over 285,000 pages of extensive science-based evidence demonstrating how Bidi(TM) Sticks are “Appropriate for the Protection of Public Health” (“APPH”).

“Bidi(TM) Stick is a premium-quality product that adult smokers have discovered can be a viable alternative to combustible tobacco, and we look forward to meeting the increasing market demand for the innovative product,” said Kaival Brands president and CEO Kaival Niraj Patel.

Using science as a foundational base, Bidi(TM) Vapor engineered its electronic nicotine-delivery system (“ENDS”) products using its own patented technology. With stringent quality control standards in place, the company vetted all supplementary raw chemicals and components purchased for the manufacturing process in a cGMP (current Good Manufacturing Practice) facility. Following strict in-vitro and in-vivo toxicity testing (including genotoxicity tests) at a GLP (Good Laboratory Practice)-approved lab, the product was then subjected to an HPHC (Harmful and Potentially Harmful Constituents) analysis of both the aerosol and e-liquid in ISO 17025 certified labs.

Also contained in the PMTA submission were three independent surveys and one combined consumer survey of people aged 21+ conducted by Bidi(TM) Vapor. The application also included specific information concerning the product’s 11 flavors in addition to details on its nicotine concentration that stands at 6% weight/volume.

“Both Kaival Brands and Bidi(TM) Vapor fully support proper regulation of the category so that all ENDS products meet the highest manufacturing, safety and marketing standards for adult smokers, with the ultimate goal of improving public health,” Patel continued. “We look forward to working with Kaival Brands as we work with the FDA to construct its regulatory policy based on science and facts.”

Kaival Brands is dedicated to developing innovative and viable options for adults currently using combustible tobacco products who are opting for a healthier and more satisfying experience. The company intends to set high standards and transform perceptions with the overall goal of exceeding customer expectations and increasing market share in the continuously growing vaping industry.

For more information, visit the company’s website at www.KaivalBrands.com.

NOTE TO INVESTORS: The latest news and updates relating to KAVL are available in the company’s newsroom at http://ibn.fm/KAVL

From Our Blog

Longeveron Inc. (NASDAQ: LGVN) Discusses 2023 Progress and 2024 Plans in Corporate Update

March 28, 2024

Longeveron (NASDAQ: LGVN), a clinical-stage biotechnology company developing regenerative medicine for life-threatening conditions with unmet medical needs, recently released its full-year results for the period ended December 31, 2023, and provided a corporate update (https://ibn.fm/iORBu). Results from multiple studies using Longeveron’s lead investigational therapeutic candidate, Lomecel-B(TM), were announced by the company last year. “In 2023 […]

Rotate your device 90° to view site.